

# Thomas P Ahern

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7391736/thomas-p-ahern-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48  
papers

1,349  
citations

17  
h-index

36  
g-index

50  
ext. papers

1,562  
ext. citations

4.6  
avg, IF

4.29  
L-index

#	Paper	IF	Citations
48	Improving the transparency of meta-analyses with interactive web applications. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> , 26, 327-332	2.7	3
47	Ultrasound for the Objective Measurement of Breast Lymphedema. <i>Journal of Ultrasound in Medicine</i> , <b>2021</b> ,	2.9	1
46	Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin. <i>Acta Oncologica</i> , <b>2020</b> , 59, 1009-1015	3.2	2
45	Bayesian Pathway Analysis for Complex Interactions. <i>American Journal of Epidemiology</i> , <b>2020</b> , 189, 1610-1622	3.622	2
44	Use of phthalate-containing prescription drugs and the risk of gastric cancer: a Danish nationwide case-control study. <i>Acta Oncologica</i> , <b>2019</b> , 58, 852-858	3.2	1
43	Exposure to phthalate-containing prescription drugs and the risk of colorectal adenocarcinoma: A Danish nationwide case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 528-535	2.6	1
42	Circulating lipids, mammographic density, and risk of breast cancer in the Nurses' Health Study and Nurses' Health Study II. <i>Cancer Causes and Control</i> , <b>2019</b> , 30, 943-953	2.8	1
41	Towards a more precise and individualized assessment of breast cancer risk. <i>Aging</i> , <b>2019</b> , 11, 1305-1316	5.6	8
40	Postoperative opioid prescribing patterns and use after vascular surgery. <i>Vascular Medicine</i> , <b>2019</b> , 24, 63-69	3.3	13
39	Expression of survivin does not appear to influence breast cancer recurrence risk. <i>Acta Oncologica</i> , <b>2019</b> , 58, 154-161	3.2	1
38	Post-Discharge Opioid Prescribing and Use after Common Surgical Procedure. <i>Journal of the American College of Surgeons</i> , <b>2018</b> , 226, 1004-1012	4.4	108
37	Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction. <i>Human Reproduction</i> , <b>2018</b> , 33, 503-511	5.7	14
36	Cumulative exposure to phthalates from phthalate-containing drug products: a Danish population-wide study. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 1798-1805	3.8	8
35	Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. <i>BMJ Open</i> , <b>2018</b> , 8, e021805	3	9
34	Pharmacoepidemiology in Pharmacogenetics. <i>Advances in Pharmacology</i> , <b>2018</b> , 83, 109-130	5.7	3
33	Statins: a role in breast cancer therapy?. <i>Journal of Internal Medicine</i> , <b>2018</b> , 284, 346-357	10.8	53
32	Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. <i>Acta Oncologica</i> , <b>2018</b> , 57, 120-128	3.2	8

31	The Impact of an Acute Care Surgery Model on General Surgery Service Productivity. <i>Perioperative Care and Operating Room Management</i> , <b>2018</b> , 12, 26-30	0.5	3
30	Adjustment disorder and type-specific cancer incidence: a Danish cohort study. <i>Acta Oncologica</i> , <b>2018</b> , 57, 1367-1372	3.2	3
29	Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2152-2161	3.8	20
28	Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2017</b> , 26, 938-944	4	19
27	Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. <i>Acta Oncologica</i> , <b>2017</b> , 56, 1155-1160	3.2	10
26	Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort. <i>American Journal of Epidemiology</i> , <b>2017</b> , 186, 679-687	3.8	23
25	Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 428-434	3.9	10
24	Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 75-85	3.8	27
23	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1179-1188	2.2	71
22	Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171453	3.7	5
21	Development of a predictive miRNA signature for breast cancer risk among high-risk women. <i>Oncotarget</i> , <b>2017</b> , 8, 112170-112183	3.3	17
20	Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 96-102	8.7	11
19	Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study. <i>Acta Oncologica</i> , <b>2016</b> , 55, 734-41	3.2	4
18	Opioids and breast cancer recurrence: A Danish population-based cohort study. <i>Cancer</i> , <b>2015</b> , 121, 3507-64	6.4	56
17	Digoxin use and risk of invasive breast cancer: evidence from the NursesTHealth Study and meta-analysis. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 144, 427-35	4.4	24
16	Statins and breast cancer prognosis: evidence and opportunities. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e461-8	21.7	128
15	Manganese superoxide dismutase and breast cancer recurrence: a Danish clinical registry-based case-control study, and a meta-analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e87450	3.7	4
14	Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2419-2425	10.3	13

13	Use of $\beta$ -blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2265-72	2.2	82
12	Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. <i>Acta Oncologica</i> , <b>2012</b> , 51, 254-61	3.2	8
11	Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 1461-8	9.7	257
10	The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable. <i>American Journal of Epidemiology</i> , <b>2011</b> , 174, 1382-90	3.8	13
9	CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 489-500	9.7	76
8	Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. <i>Clinical Epidemiology</i> , <b>2010</b> , 2, 241-6	5.9	16
7	Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. <i>Acta Oncologica</i> , <b>2010</b> , 49, 305-12	3.2	73
6	Lifetime tobacco smoke exposure and breast cancer incidence. <i>Cancer Causes and Control</i> , <b>2009</b> , 20, 1837-44	2.4	20
5	Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. <i>Medical Care</i> , <b>2009</b> , 47, 73-9	3.1	46
4	Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 616-21	8.7	50
3	Comment on Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. <i>Cancer Science</i> , <b>2008</b> , 99, 1706-7	6.9	5
2	Modification of tamoxifen response: what have we learned?. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1764-5; author reply 1765-6	2.2	10
1	Trends in breast-conserving surgery in Denmark, 1982-2002. <i>European Journal of Epidemiology</i> , <b>2008</b> , 23, 109-14	12.1	9